Initial results from baseline samples collected as part of the Pilot study, as published in the New England Journal of Medicine http://www.nejm.org/doi/full/10.1056/NEJMoa1511410:
Figure 1. Results on Quantitative RT-PCR in Initial Semen Specimens Obtained from Survivors of Ebola Virus Disease, According to Time after Symptom Onset.
We performed quantitative reverse transcriptase–polymerase chain reaction (RT-PCR) testing using Ebola virus–specific gene targets (NP and VP40) and the human β2-microglobulin (B2M) gene, as described previously.1,2 We considered the findings to be positive if the VP40 and the NP gene targets were both detected within 40 cycles of replication. The findings were considered to be negative if neither of the Ebola virus gene target was detected, nor the findings regarding β2M status were positive. The findings were ruled to be indeterminate if either the VP40 or the NP gene target was detected, but not both.